LRRK2 phosphorylation of Rab GTPases in Parkinson’s disease

By Suzanne Pfeffer, PhD
View Published Article

Output Details

Description

This review highlights new findings related to LRRK2-mediated phosphorylation of Rab GTPases and its consequences.

Identifier (DOI)
10.1002/1873-3468.14492
Tags
  • LRRK2
  • Rab GTPases
  • Review
Team
Team Alessi
Program
Collaborative Research Network
Theme
PD Functional Genomics

Meet the Authors

Related Research

End-product inhibition of the LRRK2-counteracting PPM1H phosphatase

PPM1H phosphatase reverses Rab GTPase phosphorylation by LRRK2 in Parkinson's disease. PPM1H binds Rab8A and Rab10 at an allosteric site, inhibiting phosphatase activity. Targeting this site may offer a therapeutic strategy.

View Article

PPM1M, a LRRK2-counteracting, phosphoRab12-preferring phosphatase with potential link to Parkinson’s disease

LRRK2 phosphorylates Rab GTPases linked to Parkinson's disease. PPM1M identified as a phosphatase reversing Rab phosphorylation, crucial in LRRK2 pathway. PPM1M mutation found in Parkinson's patients, suggesting a new therapeutic target.

View Article

GPNMB is a biomarker for lysosomal dysfunction and is secreted via LRRK2-modulated lysosomal exocytosis

*GPNMB* is linked to Parkinson's Disease as a risk factor, affecting its transcription and protein levels in CSF. Macrophages secrete GPNMB in response to lysosomal stress through lysosomal exocytosis, with LRRK2 influencing its secretion.

View Article
View More Outputs